Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination

Abstract Myocarditis and pericarditis are frequent complications of COVID-19, but have also been reported following vaccination against COVID-19 in adolescents. To build vaccine confidence and inform policy, we characterized the incidence of myocarditis/pericarditis in adolescents following BNT162b2...

Full description

Bibliographic Details
Main Authors: Patrick D. M. C. Katoto, Liliane N. Byamungu, Amanda S. Brand, Jacques L. Tamuzi, Mireille A. M. Kakubu, Charles S. Wiysonge, Glenda Gray
Format: Article
Language:English
Published: Nature Portfolio 2023-06-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-023-00681-3
_version_ 1797420754629820416
author Patrick D. M. C. Katoto
Liliane N. Byamungu
Amanda S. Brand
Jacques L. Tamuzi
Mireille A. M. Kakubu
Charles S. Wiysonge
Glenda Gray
author_facet Patrick D. M. C. Katoto
Liliane N. Byamungu
Amanda S. Brand
Jacques L. Tamuzi
Mireille A. M. Kakubu
Charles S. Wiysonge
Glenda Gray
author_sort Patrick D. M. C. Katoto
collection DOAJ
description Abstract Myocarditis and pericarditis are frequent complications of COVID-19, but have also been reported following vaccination against COVID-19 in adolescents. To build vaccine confidence and inform policy, we characterized the incidence of myocarditis/pericarditis in adolescents following BNT162b2 vaccination and explored the association with dose and sex. We searched national and international databases for studies reporting the incidence of myocarditis/pericarditis following BNT162b2 vaccination as the primary endpoint. The intra-study risk of bias was appraised, and random-effects meta-analyses were performed to estimate the pooled incidence by dose stratified by sex. The pooled incidence of myocarditis/pericarditis was 4.5 (95%CI: 3.14–6.11) per 100,000 vaccinations across all doses. Compared to dose 1, the risk was significantly higher after dose 2 (RR: 8.62, 95%CI: 5.71–13.03). However, adolescents experienced a low risk after a booster dose than after dose 2 (RR: 0.06; 95%CI: 0.04–0.09). Males were approximately seven times (RR: 6.66, 95%CI: 4.77–4.29) more likely than females to present myocarditis/pericarditis. In conclusion, we found a low frequency of myocarditis/pericarditis after BNT162b2, which occurred predominantly after the second dose in male adolescents. The prognosis appears to be favorable, with full recovery in both males and females. National programs are recommended to adopt the causality framework to reduce overreporting, which undercuts the value of the COVID-19 vaccine on adolescent life, as well as to extend the inter-dose interval policy, which has been linked to a lower frequency of myocarditis/pericarditis.
first_indexed 2024-03-09T07:06:06Z
format Article
id doaj.art-39b6f18d170649a5982e7e79f5d2fb90
institution Directory Open Access Journal
issn 2059-0105
language English
last_indexed 2024-03-09T07:06:06Z
publishDate 2023-06-01
publisher Nature Portfolio
record_format Article
series npj Vaccines
spelling doaj.art-39b6f18d170649a5982e7e79f5d2fb902023-12-03T09:30:26ZengNature Portfolionpj Vaccines2059-01052023-06-01811910.1038/s41541-023-00681-3Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccinationPatrick D. M. C. Katoto0Liliane N. Byamungu1Amanda S. Brand2Jacques L. Tamuzi3Mireille A. M. Kakubu4Charles S. Wiysonge5Glenda Gray6Office of the President and CEO, South African Medical Research CouncilDepartment of Pediatric, Faculty of Medicine and Health Sciences, University of KwaZulu-NatalCentre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch UniversityCentre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch UniversityMinistry of Health and Social Services of NamibiaCentre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch UniversityOffice of the President and CEO, South African Medical Research CouncilAbstract Myocarditis and pericarditis are frequent complications of COVID-19, but have also been reported following vaccination against COVID-19 in adolescents. To build vaccine confidence and inform policy, we characterized the incidence of myocarditis/pericarditis in adolescents following BNT162b2 vaccination and explored the association with dose and sex. We searched national and international databases for studies reporting the incidence of myocarditis/pericarditis following BNT162b2 vaccination as the primary endpoint. The intra-study risk of bias was appraised, and random-effects meta-analyses were performed to estimate the pooled incidence by dose stratified by sex. The pooled incidence of myocarditis/pericarditis was 4.5 (95%CI: 3.14–6.11) per 100,000 vaccinations across all doses. Compared to dose 1, the risk was significantly higher after dose 2 (RR: 8.62, 95%CI: 5.71–13.03). However, adolescents experienced a low risk after a booster dose than after dose 2 (RR: 0.06; 95%CI: 0.04–0.09). Males were approximately seven times (RR: 6.66, 95%CI: 4.77–4.29) more likely than females to present myocarditis/pericarditis. In conclusion, we found a low frequency of myocarditis/pericarditis after BNT162b2, which occurred predominantly after the second dose in male adolescents. The prognosis appears to be favorable, with full recovery in both males and females. National programs are recommended to adopt the causality framework to reduce overreporting, which undercuts the value of the COVID-19 vaccine on adolescent life, as well as to extend the inter-dose interval policy, which has been linked to a lower frequency of myocarditis/pericarditis.https://doi.org/10.1038/s41541-023-00681-3
spellingShingle Patrick D. M. C. Katoto
Liliane N. Byamungu
Amanda S. Brand
Jacques L. Tamuzi
Mireille A. M. Kakubu
Charles S. Wiysonge
Glenda Gray
Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
npj Vaccines
title Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
title_full Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
title_fullStr Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
title_full_unstemmed Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
title_short Systematic review and meta-analysis of myocarditis and pericarditis in adolescents following COVID-19 BNT162b2 vaccination
title_sort systematic review and meta analysis of myocarditis and pericarditis in adolescents following covid 19 bnt162b2 vaccination
url https://doi.org/10.1038/s41541-023-00681-3
work_keys_str_mv AT patrickdmckatoto systematicreviewandmetaanalysisofmyocarditisandpericarditisinadolescentsfollowingcovid19bnt162b2vaccination
AT lilianenbyamungu systematicreviewandmetaanalysisofmyocarditisandpericarditisinadolescentsfollowingcovid19bnt162b2vaccination
AT amandasbrand systematicreviewandmetaanalysisofmyocarditisandpericarditisinadolescentsfollowingcovid19bnt162b2vaccination
AT jacquesltamuzi systematicreviewandmetaanalysisofmyocarditisandpericarditisinadolescentsfollowingcovid19bnt162b2vaccination
AT mireilleamkakubu systematicreviewandmetaanalysisofmyocarditisandpericarditisinadolescentsfollowingcovid19bnt162b2vaccination
AT charlesswiysonge systematicreviewandmetaanalysisofmyocarditisandpericarditisinadolescentsfollowingcovid19bnt162b2vaccination
AT glendagray systematicreviewandmetaanalysisofmyocarditisandpericarditisinadolescentsfollowingcovid19bnt162b2vaccination